DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma
- DLL3-expressing Tumors
- PET / CT
- Neuroendocrine Cancer
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Enrolment target
- 80
- Started
- 10 March 2026
- Main results due
- 31 December 2026
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Ages 18 years to 80 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report); * Serum ProGRP or NSE level ≥ 3 times the upper limit of normal; * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. * Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits; Exclusion Criteria: * The inability or unwillingness of the research participant or legal representative to provide written informed consent. * Inability to complete PET/CT imaging.
What this study is about
In the sponsor’s own words, from the registry.
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
Study sites(1)
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07458906. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me